Consists of Ebastine, Phenylephrine
Ebastine (Ebast DC) indications
Allergic rhinitis or chronic idiopathic urticaria, seasonal allergic rhinitis. Inhibition of histamine-induced wheal & flare reactions of the skin due to allergens or medications.
Uses of Ebastine (Ebast DC) in details
Ebastine (Ebast DC) is used to treat allergic conditions.
Ebastine (Ebast DC) description
Ebastine (Ebast DC) (trade names Kestine, Evastin, Ebastine (Ebast DC), Aleva) is a non-sedating H1 antihistamine. It does not penetrate the blood-brain barrier and thus allows an effective block of the H1 receptor in peripheral tissue without a central side effect, i.e not causing sedation or drowsiness.
Ebastine (Ebast DC) dosage
Histamine-induced wheal & flare 10 mg/day. Pruritus 10 mg/day. Severe pruritus Initially, 20 mg/day. Reduce to 10 mg/day upon improvement of itching. Allergic rhinitis or chronic idiopathic urticaria 10 mg as a single daily dose. Seasonal allergic rhinitis 20 mg/day.
Ebastine (Ebast DC) interactions
Concomitant use of ketoconazole, itraconazole, clarithromycin or erythromycin may increase plasma levels of Ebastine (Ebast DC) and cause QTc interval prolongation.
Ebastine (Ebast DC) side effects
Nausea, Drowsiness, Abdominal pain, Dry mouth, Headache, Indigestion, Insomnia, Nose bleed, Nasal infection, Sinus inflammation, Sore throat, Weakness
Ebastine (Ebast DC) contraindications
Allergic conditions including rhinitis and pruritic skin disorders
What is Phenylephrine (Ebast DC)?
Phenylephrine (Ebast DC) (Phenylephrine (Ebast DC)) is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).
Phenylephrine (Ebast DC) is used to treat nasal and sinus congestion, or congestion of the tubes that drain fluid from your inner ears, called the eustachian (yoo-STAY-shun) tubes.
Phenylephrine (Ebast DC) may also be used for purposes not listed in this medication guide.
Phenylephrine (Ebast DC) indications
Phenylephrine (Ebast DC) is used for the temporary relief of stuffy nose, sinus, and ear symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis). This medication works by decreasing swelling in the nose and ears, thereby lessening discomfort and making it easier to breathe.
Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely.
How should I use Phenylephrine (Ebast DC)?
Use Phenylephrine (Ebast DC) as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Phenylephrine (Ebast DC) is for use in the eye only. Avoid contact with the nose or mouth.
- To use Phenylephrine (Ebast DC), first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eye for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including your eye. Keep the container tightly closed.
- Do not wear contact lenses while you are using Phenylephrine (Ebast DC). Sterilize contact lenses according to the manufacturer's directions and check with your doctor before using them.
- Do not use Phenylephrine (Ebast DC) if it is brown or contains particles.
- If you miss a dose of Phenylephrine (Ebast DC), use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Phenylephrine (Ebast DC).
Uses of Phenylephrine (Ebast DC) in details
Use: Labeled Indications
Hypotension/shock: Treatment of hypotension, vascular failure in shock. Note: Not recommended for routine use in the treatment of septic shock; use should be limited until more evidence demonstrating positive clinical outcomes becomes available (Rhodes 2017).
Guideline recommendations:
Cardiogenic shock: The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends Phenylephrine (Ebast DC), if needed, be considered for initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction (AHA [van Diepen 2017]).
Hypotension during anesthesia: As a vasoconstrictor in regional analgesia
Nasal congestion: As a decongestant [OTC]
Off Label Uses
Hypotension in patients with obstructive hypertrophic cardiomyopathy
Phenylephrine (Ebast DC) is a pure alpha1 agonist that will increase systemic vascular resistance without increasing heart rate or contractility. This is advantageous in patients with obstructive hypertrophic cardiomyopathy and hypotension since increases in both heart rate and contractility may cause the obstruction to worsen, leading to a decrease in cardiac output. Other vasopressors like dopamine, epinephrine, and norepinephrine may increase contractility and/or heart rate. Additional trials may be necessary to further define the role of Phenylephrine (Ebast DC) in this condition.
Based on the American Urological Association guidelines for the management of priapism, due to the low risk of cardiovascular side effects intracavernous injection of Phenylephrine (Ebast DC) is recommended for ischemic priapism that persists following aspiration/irrigation.
Phenylephrine (Ebast DC) description
Phenylephrine (Ebast DC) is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Phenylephrine (Ebast DC) dosage
Phenylephrine (Ebast DC) Dosage
Generic name: Phenylephrine (Ebast DC) HYDROCHLORIDE 10mg in 1mL
Dosage form: injection
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
General Dosage and Administration Instructions
Phenylephrine (Ebast DC) (Phenylephrine (Ebast DC) hydrochloride) Injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:
- Bolus: Dilute with normal saline or 5% dextrose in water.
- Continuous infusion: Dilute with normal saline or 5% dextrose in water.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.
During Phenylephrine (Ebast DC) administration:
- Correct intravascular volume depletion.
- Correct acidosis. Acidosis may reduce the effectiveness of Phenylephrine (Ebast DC).
Dosing for Treatment of Hypotension during Anesthesia
The following are the recommended dosages for the treatment of hypotension during anesthesia.
- The recommended initial dose is 40 to 100 mcg administered by intravenous bolus. May administer additional boluses every 1-2 minutes as needed; not to exceed a total dosage of 200 mcg.
- If blood pressure is below the target goal, start a continuous intravenous infusion with an infusion rate of 10 to 35 mcg/minute; not to exceed 200 mcg/minute.
- Adjust dosage according to the blood pressure goal.
Prepare a 100 mcg/mL Solution for Bolus
Intravenous Administration
For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of Phenylephrine (Ebast DC):
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Ebast DC) and dilute with 99 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
- Withdraw an appropriate dose from the 100 mcg/mL solution prior to bolus intravenous administration.
Prepare a Solution for Continuous
Intravenous Administration
For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of Phenylephrine (Ebast DC) in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:
- Withdraw 10 mg (1 mL of 10 mg/mL) of Phenylephrine (Ebast DC) and dilute with 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP.
Directions for Dispensing from Pharmacy Bulk Vial
The Pharmacy Bulk Vial is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.
More about Phenylephrine (Ebast DC) (Phenylephrine (Ebast DC))
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Phenylephrine (Ebast DC)
- Phenylephrine (Ebast DC) (Advanced Reading)
- Other brands: Neo-Synephrine, Phenylephrine (Ebast DC) Congestion, Sudogest PE, Phenylephrine (Ebast DC) Children's Nasal Decongestant, More (9) »
Professional resources
- Phenylephrine (Ebast DC) (FDA)
- Phenylephrine (Ebast DC) Hydrochloride (AHFS Monograph)
Related treatment guides
- Hypotension
Phenylephrine (Ebast DC) interactions
See also:
What other drugs will affect Phenylephrine (Ebast DC)?
Acetaminophen: May increase the serum concentration of Phenylephrine (Ebast DC) (Systemic). Monitor therapy
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Ebast DC) (Systemic). Monitor therapy
CloZAPine: May diminish the therapeutic effect of Phenylephrine (Ebast DC) (Systemic). Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Ebast DC) (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of Phenylephrine (Ebast DC). Use of hyaluronidase for other purposes in patients receiving Phenylephrine (Ebast DC) may be considered as clinically indicated. Avoid combination
Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination
Ioflupane I 123: Phenylephrine (Ebast DC) (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Propacetamol: May increase the serum concentration of Phenylephrine (Ebast DC) (Systemic). Management: Monitor patients closely for increased side effects of Phenylephrine (Ebast DC) if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy
Phenylephrine (Ebast DC) side effects
See also:
What are the possible side effects of Phenylephrine (Ebast DC)?
Applies to Phenylephrine (Ebast DC): intravenous solution
As well as its needed effects, Phenylephrine (Ebast DC) (the active ingredient contained in Phenylephrine (Ebast DC)) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking Phenylephrine (Ebast DC), check with your doctor or nurse immediately:
Incidence not known:
- Blurred vision
- chest pain or discomfort
- difficult or labored breathing
- dizziness
- fainting
- fast, slow, or irregular heartbeat
- headache
- nausea or vomiting
- nervousness
- pain in the shoulders, arms, jaw, or neck
- pounding in the ears
- sweating
- tightness in the chest
- unusual tiredness
If any of the following symptoms of overdose occur while taking Phenylephrine (Ebast DC), get emergency help immediately:
Symptoms of overdose:
- Feeling of fullness in the head
- pounding or rapid pulse
- tingling in the arms or legs
- vomiting
Minor Side Effects
Some Phenylephrine (Ebast DC) side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:
Incidence not known:
- Heartburn
- itching skin
- nausea
- pain in the neck
- pain or discomfort in chest, upper stomach, or throat
Phenylephrine (Ebast DC) contraindications
See also:
What is the most important information I should know about Phenylephrine (Ebast DC)?
Minims Phenylephrine (Ebast DC) hydrochloride should not be used in patients with severe hypertension, ventricular tachycardia, or in patients who are hypersensitive to it or to any of the components.
Active ingredient matches for Ebast DC:
Unit description / dosage (Manufacturer) | Price, USD |
EBAST DC 10 MG/10 MG TABLET 1 strip / 10 tablets each (Micro Labs Ltd) | $ 0.96 |
List of Ebast DC substitutes (brand and generic names): | |
EBA-P (India) | |
100's (Blubell) | $ 6.02 |
Eba-P Ebastine 10 mg, Phenylephrine10 mg. TAB / 100 (Blubell) | $ 6.02 |
EBA-P tab 10's (Blubell) | $ 0.60 |
Eba-P Ebastine 10 mg, Phenylephrine10 mg. TAB / 100 (Blubell) | $ 6.02 |
EBAST-DC (India) | |
10's (Micro Labs) | $ 0.71 |
Ebast-DC Ebastine 10 mg, Phenylephrinehydrochloride 10 mg. TAB / 10 (Micro Labs) | $ 0.71 |
EBAST-DC tab 10's (Micro Labs) | $ 0.71 |
Ebast-DC Ebastine 10 mg, Phenylephrinehydrochloride 10 mg. TAB / 10 (Micro Labs) | $ 0.71 |
Ebastine/Phenylephrine (India) | |
Erostin-DC (India) | |
10's (Micro Eros) | $ 0.71 |
Erostin-DC Ebastin 10mg, Phenylephrine10mg FC -TAB / 10 (Micro Eros) | $ 0.71 |
EROSTIN-DC film-coated tab 10's (Micro Eros) | $ 0.71 |
References
- PubChem. "phenylephrine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "ebastine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Ebastine". http://www.drugbank.ca/drugs/DB11742 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Ebast DC are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ebast DC. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Ebast DC drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
Users | % | ||
---|---|---|---|
Useful | 1 | 100.0% |
Consumer reported price estimates
No survey data has been collected yet2 consumers reported time for results
To what extent do I have to use Ebast DC before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes > 3 month and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Ebast DC. To get the time effectiveness of using Ebast DC drug by other patients, please click here.
Users | % | ||
---|---|---|---|
> 3 month | 1 | 50.0% | |
1 day | 1 | 50.0% |
6 consumers reported age
Users | % | ||
---|---|---|---|
30-45 | 4 | 66.7% | |
16-29 | 2 | 33.3% |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology